Stockreport

Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome

Anavex Life Sciences Corp.  (AVXL) 
NASDAQ:AMEX Investor Relations: anavex.com/share-data
PDF NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developin [Read more]